What is the dosing protocol for atropine in treating hypotension and bradycardia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Atropine Protocol for Hypotension and Bradycardia

For symptomatic bradycardia with hypotension, administer atropine 0.5 mg IV every 3-5 minutes up to a maximum total dose of 3 mg, while preparing for transcutaneous pacing if the patient does not respond to atropine. 1, 2

Indications for Atropine

  • Symptomatic sinus bradycardia (heart rate <50 bpm with hypotension, ischemia, or escape ventricular arrhythmia) 3
  • Ventricular asystole 3
  • Symptomatic AV block occurring at the AV nodal level (second-degree type I or third-degree with narrow-complex escape rhythm) 3
  • Bradycardia with hemodynamic compromise (hypotension, altered mental status, chest pain, acute heart failure, shock) 1

Dosing Protocol

  • Initial dose: 0.5 mg IV 1, 2
  • Repeat every 3-5 minutes as needed 3, 1
  • Maximum total dose: 3 mg 1, 2
  • Titrate to achieve minimally effective heart rate (approximately 60 bpm) 3
  • For patients with coronary artery disease, limit total dose to 0.03-0.04 mg/kg 2

Important Cautions

  • Doses less than 0.5 mg may paradoxically worsen bradycardia due to parasympathomimetic effects 3, 1
  • Use with caution in acute myocardial infarction as increased heart rate may worsen ischemia 3, 1
  • Avoid in AV block occurring at infranodal level (usually associated with anterior MI with wide-complex escape rhythm) 3
  • Use with caution in patients after cardiac transplantation as it may cause paradoxical AV block 3, 1
  • Monitor for potential hypertensive response, which although rare, can be severe 4

When Atropine Fails

  • Consider transcutaneous pacing for unstable patients not responding to atropine 3, 1
  • Consider β-adrenergic support with dopamine (2-10 μg/kg/min) or epinephrine (2-10 μg/min) 3, 1
  • Prepare for transvenous pacing if patient does not respond to drugs or transcutaneous pacing 3

Clinical Evidence of Effectiveness

  • Atropine has been shown to significantly increase heart rate (from 46±14 to 79±12/min) and systolic blood pressure (from 70±15 to 105±13 mm Hg) in patients with bradycardia-hypotension syndrome 5
  • In patients with acute myocardial infarction and sinus bradycardia, atropine has been shown to normalize blood pressure in 88% of hypotensive patients 6
  • Prophylactic atropine administration before procedures that may induce bradycardia (such as carotid angioplasty) has been shown to decrease the incidence of intraoperative bradycardia and cardiac morbidity 7

Potential Adverse Effects

  • Tachycardia, which may worsen ischemia in patients with acute coronary syndrome 1
  • Ventricular tachycardia or fibrillation (rare) 6
  • Central nervous system effects (hallucinations, fever) with repeated administration 1
  • Adverse effects correlate with higher initial doses (≥1.0 mg) or cumulative doses exceeding 2.5 mg over 2.5 hours 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.